International Trade

Earlier this week, BIO submitted a letter and white paper to the U.S. Trade Representative outlining recommendations for policies to pursue with TPP negotiating partners to ensure intellectual property protection for innovative biologic products.

It is imperative that the TPP create a set of strong intellectual property standards – particularly those governing data protection, patents and trade secret protection – that are relevant to biological products.

The fifth annual edition of Scientific American Worldview explores ongoing challenges and opportunities in the biopharmaceutical industry, including the looming potential of an “innovation cliff.”

Biotechnology helps societies solve old problems in new ways. Through the science of using living cells and the discovery of new molecules, biotech innovation provides societies with innovative means to address their most urgent needs: fighting disease, feeding the hungry, and improving the environment.

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.

This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and provides a review and analysis of the existing body of knowledge concerning the role of IPRs.

Successful multi-sector global health programs engage partners and policymakers early, communicate openly and frequently with relevant stakeholders, and empower and involve communities, according to a website relaunched this week, Case Studies for Global Health.

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have collaborated on a new report that builds upon the findings in BVGH’s previous analysis, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

Dr. Cohen discusses the plight of today’s emerging biotech companies, and how the federal government can best support innovation within the industry.

What does the future hold for the biotechnology industry in Japan? The Japanese government has made great strides to boost biotech within its borders.

Pavilions attract attendees and media alike, affording a space to tell your story within the context of a particular geographic region or specific focus area.

In this informative editorial Jim Greenwood, BIO President and CEO, presents an insight into China’s growing role in the future of biotechnology.

Letters, Testimony & Comments

February 9 2015
The Biotechnology Industry Organization (BIO) appreciates the opportunity to participate in the Special 301 process and is hopeful that our contribution will assist the United States Trade Representative’s (USTR) efforts in preserving strong intellectual property protections for United States’ companies internationally. BIO appreciates the opportunity to comment on 2015 Special 301 Review: Identification of Countries Under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.
June 19 2013
The TTIP represents a profoundly important opportunity to advance progress in these areas. The following comments represent BIO’s initial suggestions for the formulation of negotiating objectives relevant to biotechnology.  
June 3 2013
BIO appreciates the opportunity to respond to the Request for Comments issued by the U.S. Trade Representative on objectives to be pursued in the negotiation of a Transatlantic Trade and Investment Partnership (TTIP) agreement. 
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.

Press Releases

July 29 2015
Today BIO joined a coalition of organizations urging the Government of Japan to maintain the established reimbursement pricing structure for pharmaceuticals and medical devices.
June 20 2012
The Biotechnology Industry Organization(BIO) unveiled a report on the role of intellectual property rights in encouraging upstream research and development as well as downstream commercialization of biotechnology at the 2012 BIO International Convention.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
February 21 2011
The Biotechnology Industry Organization (BIO) stresses the critical importance of protecting intellectual property abroad in comments recently filed with the U.S. Trade Representative (USTR) on the 2011 Special 301 Review.
April 6 2010
The Obama Administration has made substantial progress to avoid retaliatory measures in a long-running “cotton dispute” brought by Brazil against the United States.